Head of Care Solutions - Employer and Payer
About the job
- A bachelor's degree in business, healthcare, or a related field, plus 15 or more years of relevant experience in enterprise sales, strategy consulting, or business development focused on technology software as a service and care management operations.
- Deep understanding of care management companies and health plan administrative technologies.
- Experience selling complex solutions and driving significant revenue growth.
- Consultative, hands-on, and collaborative approach, with communication, presentation, and analytical skills.
- Drive the technical sales lifecycle for care solutions, data platforms, and artificial intelligence applications within the employer and payer segments.
- Partner with Commercial teams from lead generation through close, including delivering value propositions, executing contracts, and meeting revenue and bookings targets.
- Map client organizational structures to uncover new business opportunities and build long-term transformational partnerships.
- Serve as a subject matter expert in population health artificial intelligence and data tools; collaborate with Product and Marketing to train internal teams and develop external-facing technical tools.
- Gather customer feedback on market trends, pricing, and competitors to influence internal product roadmaps and company milestones.
- Ability to work with complex technical software and service offerings, and processes involving multiple stakeholders.
- Ability to take initiative, work efficiently, and respond quickly to changes in a dynamic environment.
- Experience with Google productivity applications, including Gmail, Google Calendar, Sheets, Slides, and Docs.
Who We Are
Verily Health is a data platform and technology company purpose-built to power AI-enabled precision health solutions that accelerate research and improve care for individuals and communities. Uniquely positioned at the intersection of technology, data science, and healthcare, Verily transforms multimodal health data into insights, models, and actions that make healthcare more personalized, predictive, and precise.
Description
Verily exists to bring the promise of precision health to everyone everyday, and our breadth of solutions of care, research, health financing, and population health monitoring serve customers across various market segments.
As the Technical Solution Leader for Payer/Employer Segment, you will be responsible for managing the technical sales process to bring Verily’s Data & Technology solutions to existing and new Payer and Employer clients. This will include understanding customer needs, organization structure and buying patterns; developing deep and broad relationships within each account under your purview; collaborating with Verily Commercial and Customer Success teams to bring Verily breadth of solutions into your Payer and Employer clients; and holding responsibility for bookings and revenue generation associated with the products.
The role will support all care solutions technical sales processes as well as the PRE, Data Platform and AI applications in the employer and payer segment.
You will work cross functionally within each Verily Commercial Team and with Solutions Delivery and Implementation colleagues across Verily. This role will require you to be flexible and nimble and aggressively grow the business to help establish Verily as the premier solution for precision health.
Candidates located in San Bruno, Boston or Dallas are strongly encouraged to apply. This will be a remote position as the expectation is that the role will directly interface with customers and be external-facing.
Responsibilities
Drive the technical sales lifecycle for care solutions, Data Platforms, and AI applications within the employer and payer segments.
Partner with Commercial teams from lead generation to close, including value proposition delivery, contract execution, and meeting revenue/booking targets.
Map client organizational structures to uncover new business opportunities and build long-term transformational partnerships.
Serve as an SME in population health AI/data tools; collaborate with Product and Marketing to train internal teams and develop external-facing technical tooling.
Gather customer feedback on market trends, pricing, and competitors to influence internal product roadmaps and company milestones.
Qualifications
Minimum Qualifications
Bachelor’s degree in business, healthcare or related field. Plus 15+ years of relevant experience in enterprise sales, strategy consulting or business development focused on Technology SaaS and care management operations.
Deep understanding of care management companies and health plan administrative technologies.
Experience selling complex solutions and driving significant revenue growth.
Highly consultative, hands on and collaborative. Excellent communication, presentation and analytical skills.
Preferred Qualifications
Proven ability to work with complex, technical software and service offerings, and processes involving multiple stakeholders.
Ability to take initiative, work efficiently and respond quickly to changes and a dynamic environment.
A positive attitude, open mind, entrepreneurial mindset and a desire to collaborate and learn.
Connection to Verily’s corporate purpose … to bring the promise of precision health to everyone, every day.
Experience with Google suite of productivity applications (gMail, gCalendar, Sheets, Slides, Docs).
Qualified applicants must not require employer sponsored work authorization now or in the future for employment in the United States.
The US base salary range for this full-time position is $166,000 - $250,000 + bonus + benefits. Our salary ranges are determined by role, level, and location. The range displayed on each job posting reflects the minimum and maximum target for new hire salaries for the position across all US locations. Within the range, individual pay is determined by work location and additional factors, including job-related skills, experience, and relevant education or training. Your recruiter can share more about the specific salary range for your preferred location during the hiring process.
Please note that the compensation details listed in US role postings reflect the base salary only, and do not include bonus, equity, or benefits.
Verily Health Inc. is an equal opportunity employer. Qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability or protected veteran status. For our EEO Policy Statement, pleaseclick here. If you'd like more information on your EEO rights under the law, please click here.
If you have a need that requires accommodation, please let us know by completing ourAccommodations for Applicants form.
About the company
Verily Life Sciences uses data science and clinical expertise to improve health outcomes through precision health. It combines medical, lifestyle, and environmental data to tailor interventions, offering products like the Baseline Platform for clinical research and COVID-19 testing, care management solutions, and medical devices. It differentiates itself by integrating diverse data at scale, pursuing health equity through Onduo, and collaborating with public sector partners while maintaining strong data security and privacy. The goal is to uncover new health insights and bring precision health to everyone, improving health outcomes across populations.
Company Size
1,001-5,000
Company Stage
Late Stage VC
Total Funding
$3.8B
Headquarters
Dallas, Texas
Founded
2015
Get referred to Verily
See people who can refer or advise you
Simplify's Take
What believers are saying
- March 19, 2026 funding gives Verily $300 million to scale AI-native precision health.
- Verily Workbench launched on AWS, expanding access for life sciences and government researchers.
- Segmed’s April 30, 2026 imaging partnership broadens Pre Exchange’s research datasets and monetization paths.
What critics are saying
- Ryan Sloan’s HIPAA lawsuit survived dismissal on September 11, 2025, exposing trust damage.
- June 9, 2026 layoffs of 58 employees signal continued reorganization and weak operating leverage.
- Alphabet’s control exit forces Verily to prove standalone demand before the new capital runs out.
What makes Verily unique
- Verily Health Inc. pairs multimodal health data, AI, and clinical workflows across Pre and Workbench.
- Its March 19, 2026 $300 million round reduced Alphabet to a minority investor.
- Samsung, Salesforce, and NIH All of Us integrations deepen Verily’s data distribution.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Company Equity
Company News
PacBio and Verily Health announce multi-year strategic collaboration to scale long-read genomics for biomedical AI. Verily Pre will connect PacBio HiFi Sequencing with governed cloud analysis, multimodal health data and AI-ready research workflows. October 19, 2026 09:05 ET | Source: PacBio MENLO PARK, Calif. and DALLAS, Oct. 19, 2026 (GLOBE NEWSWIRE) - PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, and Verily Health Inc., a healthcare data intelligence company, announced today a multi-year strategic collaboration to integrate PacBio HiFi sequencing with Verily Health's governed data and AI platform. The collaboration will link PacBio sequencing workflows to Verily Pre, combining long-read genomic data with real-world clinical data at population scale. The resulting AI-ready clinico-genomic datasets will support biomedical discovery efforts and AI model training and deployment. The collaboration addresses a growing bottleneck in biomedical AI: increasingly powerful models require biological data with greater depth, context and scale. Long-read sequencing can reveal complex genetic variants, structural changes, methylation information, and full-length RNA transcripts that are difficult to capture with short-read approaches, offering richer insights into disease biology. Yet, processing these large, complex datasets and integrating them with clinical data for model training remains fragmented, unscalable and largely bespoke. PacBio and Verily Health intend to connect those steps, making rich genomic data more accessible and usable to power the next generation of biomedical AI applications. Verily Pre already supports population-scale biomedical research, while Workbench serves more than 20,000 researchers and has supported more than 700 publications. And because PacBio HiFi whole-genome sequencing workflows already run end-to-end within the Verily Pre environment, it provides an existing and robust technical foundation for the multi-year collaboration. "This collaboration reflects a shared focus on making high-quality genomic data more accessible and useful across research and development, while creating a foundation for continued innovation in health," said Stephen Gillett, Chairman and CEO of Verily Health. "Working with PacBio, we hope to deliver a meaningful impact to researchers and innovators working to find new answers for neurology, oncology, rare disease, and other areas of critical unmet need." "PacBio HiFi sequencing offers our customers the most complete and highest quality data available, which is ideal for training AI models where the input determines the success of the output" said Mark Van Oene, President and CEO of PacBio. "Through this collaboration with Verily Health, we are building a path to turn richer biological data into AI-ready data at scale to ultimately help researchers get more from both their sequencing and their models." Verily Pre provides the foundation to build, deploy and scale intelligent applications across healthcare and life sciences. Under the collaboration, Verily Health will configure Pre Workbench to connect PacBio sequencing workflows, acting as the secure governed research environment for the aggregation, analysis, and curation of HiFi genomic datasets. The companies also plan to use the Verily Pre trusted agentic environment (TAE) to run model training and inference, enabling researchers to explore deeper, longitudinal genomic datasets and support their workflows. Over the course of the multi-year collaboration, PacBio and Verily Health plan to expand the integration to support increasingly large and complex long-read programs across research organizations, biopharma and population genomics. The companies envision a common infrastructure that can scale with increasingly large and complex long-read programs, supporting multimodal research and AI development across biopharma, clinical institutions, population genomics and other areas of precision health. About PacBio PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.comand follow @PacBio. PacBio products are provided for Research Use Only. Not for use in diagnostic procedures. About Verily Health Inc. At the intersection of technology, data science, and healthcare, Verily Health transforms complex health data into trusted intelligence, enabling health solutions that are more personal, predictive, and precise. Verily's flagship Governed Health Intelligence platform, Verily Pre, enables healthcare organizations to responsibly govern, model, and securely activate their protected health data at scale, deploying intelligence with the scientific rigor, oversight, and auditability needed for healthcare. Disclaimer: The Verily Pre platform is not a medical device and has not been evaluated by the FDA. Customers developing Software as a Medical Device (SaMD) are solely responsible for regulatory compliance. Forward looking statements This press release may contain "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the availability, uses, accuracy, advantages, quality or performance of, or benefits of using, or expected benefits of using, PacBio products or technologies, including in connection with the collaboration between PacBio and Verily Health; plans to integrate PacBio HiFi sequencing with Verily Health's governed data and AI platform to create AI-ready clinic-genomic datasets; making genomic data more accessible and usable to power future biomedical AI application and create a foundation for continued innovation in health; impact in finding new answers for neurology, oncology, rare disease, and other areas of critical unmet need; building a path to turn richer biological data into AI-ready data; Verily Health configuring Pre Workbench as secure governed research environment; the use of TAEs to run model training and inference; developing a common infrastructure capable of supporting increasingly large and complex long-read programs; and other future events. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties and could cause actual outcomes and results to differ materially from currently anticipated results, including, challenges inherent in using, and collaborating with third parties to develop, new technologies; potential product performance, interoperability and quality issues; potential regulatory issues relating to the development and use AI technologies; rapidly changing technologies and extensive competition in, and potential FDA regulatory issues relating to, genomic sequencing; unanticipated increases in costs or expenses; interruptions or delays in the supply of components or materials for, or manufacturing of, PacBio products and products under development; third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights, among others. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption "Risk Factors." These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available. Media Contacts
Verily Health has secured additional investment from NVIDIA and existing backer CU Healthcare Innovation Fund II. The funding extends Verily's March fundraising round. Current investors include Alphabet, Series X Capital, and UCHealth. The investment supports scaling of Verily's Pre Platform, a data and AI platform helping healthcare organisations deploy AI across research and care. It also backs Verily Me, the company's patient engagement offering. Verily and NVIDIA previously announced a collaboration in October 2025. Researchers using the Pre Platform can leverage NVIDIA AI libraries and B200 GPUs. Verily developed Forecast 1.0, a foundation model integrating genomics and electronic health record data to predict long-term health risks, using NVIDIA's AI stack.
Global initiative will harness wastewater as an early warning system for public health protection. Labs across the world will collect wastewater samples on Global Wastewater Day in 2027 to generate a unique snapshot of international public health. * Press release * Published on Wednesday 26 August 2026 * Last updated on Wednesday 26 August 2026 * View more announcements in Communications Researchers from CWBE at the University of Bath partnered with Bangor University have launched Global Wastewater Day (GWD), a pioneering international initiative to harness wastewater as an early warning system for future pandemics. The initiative will bring together scientists, governments, water utilities and public health organisations from around the world to establish one of the first coordinated global wastewater intelligence networks to transform wastewater from an overlooked by-product into one of the world's most powerful tools for understanding public health, environmental change and emerging global risks. The initiative aims to create a simultaneous global snapshot of health and environmental conditions through wastewater analysis, generating new insights to strengthen disease surveillance, track antimicrobial resistance, protect the environment and improve pandemic preparedness. Professor Davey Jones, from Bangor University (Wales), who is the leading the partnership, launched the initiative at the World Water Week conference in Stockholm, which brought together experts, policymakers, businesses and international organisations from across the globe. The project will coordinate a single, global day of wastewater sampling on 31 March 2027, with participating partners analysing wastewater at host labs across the world. Professor Barbara Kasprzyk-Hordern, Global Wastewater Day co-chair and Director of the University of Bath's Centre of Excellence in Water-Based Early-Warning Systems for Health Protection (CWBE), will provide the steer and deliver the chemical analysis programme of global wastewater samples with centre's new cutting-edge mass spectrometry facility. Professor Julie Barnett, Social Sciences Lead at CWBE, has also joined GWD steering committee to coordinate the ethical oversight of the initiative. The aim is to generate the first synchronised snapshot of global public health using wastewater-based epidemiology (WBE). Using established and cutting-edge methods, the programme will focus on detecting antimicrobial resistance (AMR), pathogens, pharmaceuticals, chemical indicators and other markers of human health. The initiative is being delivered in partnership between the University of Bath, Bangor University, Verily Health, the Global Consortium for Wastewater and Environmental Surveillance for Public Health (GLOWACON), the European Commission Joint Research Centre, and a growing international consortium of scientific and public health organisations. By capturing comparable information from communities around the world, Global Wastewater Day seeks to establish a new global benchmark for monitoring health and environmental change. With over 31 countries signed up to date, the initiative's long-term ambition is to create a "Planetary Health Observatory" where wastewater becomes a routine source of intelligence for understanding the interconnected health of people, animals and the environment. Professor Barbara Kasprzyk-Hordern, Director of CWBE at the University of Bath, said: "I am delighted to see this unique initiative moving forward. "Global Wastewater Day provides an important opportunity to highlight the vital role of Wastewater-Based Epidemiology in protecting public health, safeguarding the environment, and driving sustainable innovation. "As a powerful tool for monitoring population health and environmental trends, wastewater analysis will deliver actionable insights that support evidence-based decision-making and help build more resilient and sustainable communities worldwide. "With cutting-edge analytical capabilities we will generate unprecedented insights into population health, including the burden of non-communicable diseases such as diabetes and cardiovascular disease, dietary and nutritional patterns, and exposure to hazardous chemicals, including PFAS." Davey Jones, Professor of Environmental Science and Public Health at Bangor University, said: "Everything Bath do in society leaves a footprint in its wastewater. "With Global Wastewater Day Bath want to harness the information it provides to supercharge public health research across the world, helping Bath detect emerging threats earlier and build a stronger early-warning system for future pandemics. "The initiative will enable a global comparison of public health data using standardised methods, while building a long-term resource through annual repeat sampling and an open-access dataset. "A core principle of the project is accessibility and inclusivity, with a strong emphasis on supporting participation from low- and middle-income countries. "Bath want to encourage as many scientists, organisations and communities as possible to get involved, contribute data and expertise, and share the initiative with colleagues and networks who may be interested. "By working across borders, we have an unprecedented opportunity to transform wastewater from an overlooked resource into a source of global intelligence, helping to protect populations, strengthen resilience and support better decision-making for future generations." Organisations and researchers are invited to register their interest in taking part in Global Wastewater Day. Media enquiries.
Verily has raised $300 million in a funding round led by Series X Capital, with participation from Alphabet, UCHealth, the University of Colorado Anschutz and others. Alphabet remains a significant minority investor but no longer holds a controlling stake in the precision health AI company. The investment marks Verily's transition from an LLC to a corporation, now officially named Verily Health Inc. The funds will accelerate its AI-native precision health platform strategy, helping customers harmonise healthcare data and deploy actionable intelligence into research and care workflows. Verily recently announced partnerships with Samsung's Galaxy Watch and Salesforce's Agentforce Health. The company, which graduated from Google X 10 years ago as one of Alphabet's earliest ventures, aims to make healthcare more personalised, predictive and precise through AI-powered solutions.
Verily, a Google subsidiary, expands its mosquito factory in Singapore to strengthen dengue control. 26 May 2026 [PHOTO: The Straits Times] Market Info | Health & Lifestyle | Public Health Date: 1 June 2026 Region: ASEAN-O Country: Singapore Sector: Health & Lifestyle Sub-sector: Public Health Section: Market Trends Theme: Combating Infectious Diseases Verily, a subsidiary of tech giant Google, has announced a significant expansion of its sterile mosquito production facility in Singapore, marking a major milestone in the fight against dengue. This initiative leverages cutting-edge technology where sterile male mosquitoes are bred and released into the wild to mate with wild females, thereby reducing the population of mosquitoes capable of transmitting diseases like dengue. This method, known as the Sterile Insect Technique (SIT), is an eco-friendly alternative to traditional pesticides and aligns with a sustainable approach to vector control. The expansion of this facility in Singapore reflects the country's commitment to strengthening its public health capabilities in the face of challenges posed by vector-borne diseases. Dengue, in particular, remains a major concern in the region, with thousands of cases reported annually. By adopting this innovative technology, Singapore demonstrates its determination to combine science and public health to protect its population. This approach also aligns with the broader objectives of the Healthier SG strategy, which aims to enhance the resilience of the healthcare system against emerging threats. Furthermore, this initiative positions Singapore as a regional leader in biotechnology applied to public health. By collaborating with international players like Verily, the country strengthens its ability to innovate and attract investments in sustainable health solutions. Verily's sterile mosquito factory in Singapore could also serve as a model for other countries in the region facing similar challenges with mosquito-borne diseases. This expansion is a tangible example of how Singapore is leveraging technology and innovation to address complex public health challenges while contributing to global solutions for infectious disease control.